Rothschild Redburn Upgrades Moonlake Immunotherapeutics (MLTX) to Buy
Tweet Send to a Friend
Rothschild Redburn analyst Qize Ding upgraded Moonlake Immunotherapeutics (NASDAQ: MLTX) from Neutral to Buy with a price target of $40.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
